文献速递肝病消化道肿瘤与早癌

咖啡摄入与肝脏结局改善:英国生物样本库的临床、影像与蛋白质组学证据

Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-07-01

基于英国生物样本库354,957名无基线肝硬化或肝癌参与者的前瞻性分析显示,咖啡摄入量越高,肝硬化、肝细胞癌及肝病相关死亡风险呈梯度降低,每日≥5杯组风险比分别为0.68、0.53和0.58。影像学亚组中咖啡摄入与肝脏脂肪、铁及纤维炎症指标降低相关,蛋白质组学呈现一致的保护性模式。

要点

  • 每日≥5杯咖啡与肝硬化、肝癌及肝病死亡风险降低相关
  • 含咖啡因与脱咖啡因咖啡的保护关联相似
  • 咖啡摄入与肝脏脂肪、铁及纤维炎症影像指标降低相关

核心结论

  • 较高咖啡摄入与肝脏临床、影像及蛋白质组学健康指标改善相关,支持适度饮用无糖咖啡作为肝病预防的简单策略。

研究设计与样本

  • 分析英国生物样本库354,957名无基线肝硬化或肝细胞癌参与者,中位随访13年。
  • 影像亚组28,961人接受磁共振成像评估肝脏脂肪、铁及纤维炎症。
  • 蛋白质组学分析纳入44,633人,使用Olink检测。

主要发现

  • 每日≥5杯咖啡组肝硬化风险比为0.68(95%CI 0.58-0.79),肝细胞癌为0.53(95%CI 0.34-0.83),肝病相关死亡为0.58(95%CI 0.45-0.74)。
  • 含咖啡因与脱咖啡因咖啡的保护关联相似,添加糖或人工甜味剂者中关联持续存在,但添加剂使用与铁校正T1轻度升高相关。
  • 较高咖啡摄入对应较低的肝脏脂肪、铁及纤维炎症。
  • 蛋白质组学显示咖啡摄入与较高肝细胞合成及补体蛋白水平、较低纤维化及巨噬细胞活化标志物水平相关。

临床怎么用

  • 可将适度饮用无糖咖啡作为肝病预防的简单生活方式建议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Coffee consumption has been linked to a reduced risk of liver disease, but large-scale prospective studies integrating imaging biomarkers, proteomics, and intake patterns remain limited. The effects of coffee type, additives, and metabolic modifiers are also unclear. METHODS: We analyzed 354,957 UK Biobank participants without baseline cirrhosis or hepatocellular carcinoma. Coffee consumption, type (caffeinated/decaffeinated), and additives (sugar/sweeteners) were assessed by questionnaire. Incident cirrhosis, hepatocellular carcinoma, and liver-related mortality were ascertained through linked records. In a subcohort (n = 28,961) undergoing magnetic resonance imaging, hepatic fat (proton density fat fraction), iron, and fibroinflammation (iron-corrected T1) were evaluated. Proteomic profiling (n = 44,633) used Olink assays. Models were adjusted for demographic, behavioral, metabolic, and genetic covariates. RESULTS: Over a median 13-year follow-up, higher coffee intake showed a graded reduction in liver outcomes, with ≥5 cups/day group having risk reductions of cirrhosis (hazard ratio, 0.68; 95% confidence interval, 0.58-0.79), hepatocellular carcinoma (hazard ratio, 0.53; 95% confidence interval, 0.34-0.83), and liver-related mortality (hazard ratio, 0.58; 95% confidence interval, 0.45-0.74). Protective associations were similar for caffeinated and decaffeinated coffee and persisted among those adding sugar or artificial sweeteners, although additive use correlated with modestly higher iron-corrected T1. Higher coffee intake corresponded to lower hepatic fat, iron, and fibroinflammation. Proteomic analysis revealed consistent patterns: higher levels of hepatocellular synthesis and complement proteins (transthyretin, selenoprotein P, complement factor H-related protein4/5) and lower levels of fibrogenic and macrophage-activation markers (microfibril-associated protein 4, colony stimulating factor 1 receptor, ectonucleotide pyrophosphatase/phosphodiesterase 2, transthyretin) with coffee drinking. CONCLUSIONS: Higher coffee intake was associated with favorable clinical, imaging, and proteomic indicators of liver health. These multidimensional findings support moderate unsweetened coffee as a simple strategy for liver disease prevention.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kim HS, Rezaee-Zavareh MS, Wang Y, et al. Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank. Clin Gastroenterol Hepatol. 2026. PMID: 42385787. doi:10.1016/j.cgh.2026.04.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。